Communications Biology (Jun 2024)

Modulation of serotonin transporter expression by escitalopram under inflammation

  • Sergio Mena,
  • Allison Cruikshank,
  • Janet Best,
  • H. F. Nijhout,
  • Michael C. Reed,
  • Parastoo Hashemi

DOI
https://doi.org/10.1038/s42003-024-06240-3
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Selective serotonin reuptake inhibitors (SSRIs) are widely used for depression based on the monoamine deficiency hypothesis. However, the clinical use of these agents is controversial, in part because of their variable clinical efficacy and in part because of their delayed onset of action. Because of the complexities involved in replicating human disease and clinical dosing in animal models, the scientific community has not reached a consensus on the reasons for these phenomena. In this work, we create a theoretical hippocampal model incorporating escitalopram’s pharmacokinetics, pharmacodynamics (competitive and non-competitive inhibition, and serotonin transporter (SERT) internalization), inflammation, and receptor dynamics. With this model, we simulate chronic oral escitalopram in mice showing that days to weeks are needed for serotonin levels to reach steady-state. We show escitalopram’s chemical efficacy is diminished under inflammation. Our model thus offers mechanisms for how chronic escitalopram affects brain serotonin, emphasizing the importance of optimized dose and time for future antidepressant discoveries.